Sandoz to invest $90M in Slovenia site that will produce biosimilars

San­doz is in­vest­ing $90 mil­lion to build a biosim­i­lar de­vel­op­ment cen­ter in Ljubl­jana, Slove­nia, the sec­ond ma­jor in­vest­ment that the gener­ics mak­er has made in the coun­try so far this year.

San­doz plans to build a new fa­cil­i­ty that is ex­pect­ed to bol­ster its ca­pa­bil­i­ties to pro­duce drug sub­stances and de­vel­op biosim­i­lars, the com­pa­ny said in a press re­lease. It plans to cre­ate 200 new jobs at the cen­ter, which is set to be com­plet­ed by 2026.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN